Fact CheckerSign in

NCT07326631Not yet recruiting

Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure

Source: ClinicalTrials.gov · Last updated 8 Jan 2026

Brief summary (registry, in English)

To assess the effect of Finerinone on slowing renal function decline and improving cardiovascular outcomes, particularly heart failure risk, in patients with diabetic CKD.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
120 (estimated)
First submitted
9 Dec 2025
Start date
1 Jan 2026
Primary completion date
30 Jun 2026
Lead sponsor
College of Physicians and Surgeons Pakistan
NCT number
NCT07326631

What you commit to

  • Study type: Interventional
  • Planned participants: 120
  • From 1 Jan 2026 to the primary completion date, 30 Jun 2026
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Symptomatic heart failure (NYHA class II-IV).
  • Known non-diabetic kidney disease.
  • Contraindication or hypersensitivity to finerenone.
  • Any condition limiting compliance or follow-up.

Lab values

  • eGFR \<25 mL/min/1.73m² or on maintenance dialysis.
  • Serum potassium \>4.8 mmol/L or history of severe hyperkalaemia.

Other

  • Recent major cardiovascular event (within 30 days).
  • Pregnancy or lactation.

Who the study is looking for

  • Adults aged ≥18 years.
  • Diagnosed cases of type 2 diabetes mellitus.
  • Chronic kidney disease with eGFR 25-90 mL/min/1.73m² and/or UACR ≥30 mg/g.
  • On stable ACE inhibitor or ARB therapy for at least 4 weeks.
  • Serum potassium ≤4.8 mmol/L.
  • Provided written informed consent.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.